CLINICAL TRIALS PROFILE FOR RABEPRAZOLE SODIUM
✉ Email this page to a colleague
505(b)(2) Clinical Trials for RABEPRAZOLE SODIUM
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT01286194 ↗ | A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms | Completed | Eisai Inc. | 2006-04-01 | This is a multi-center, open-label, all-comers OTC actual use study in pharmacy sites where the principal investigator will be a pharmacist. | |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for RABEPRAZOLE SODIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00125736 ↗ | A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium | Completed | Eisai Co., Ltd. | Phase 4 | 2005-08-01 | The purpose of this study is to investigate the efficacy and safety of combination use of E0671 and Rabeprazole Sodium in patients with gastric ulcer. |
| NCT00125736 ↗ | A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium | Completed | Eisai Limited | Phase 4 | 2005-08-01 | The purpose of this study is to investigate the efficacy and safety of combination use of E0671 and Rabeprazole Sodium in patients with gastric ulcer. |
| NCT00132496 ↗ | Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole | Completed | Eisai Inc. | Phase 2 | 2005-08-01 | The primary objective of this study is to collect safety information on rabeprazole 10 mg and 20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16 years. The secondary objectives are to assess the efficacy of rabeprazole on the improvement of the symptoms of GERD and to explore the relationship of symptom relief to dose received, based on symptom frequency and severity, antacid use, and quality of life (QOL) measures. |
| NCT00165646 ↗ | A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease | Completed | Eisai Co., Ltd. | Phase 3 | 2004-09-01 | To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind, comparative study. |
| NCT00165672 ↗ | A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease | Completed | Eisai Limited | Phase 3 | 2005-05-01 | To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)). |
| NCT00165672 ↗ | A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease | Completed | Eisai Inc. | Phase 3 | 2005-05-01 | To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RABEPRAZOLE SODIUM
Condition Name
Clinical Trial Locations for RABEPRAZOLE SODIUM
Trials by Country
Clinical Trial Progress for RABEPRAZOLE SODIUM
Clinical Trial Phase
Clinical Trial Sponsors for RABEPRAZOLE SODIUM
Sponsor Name
